title: Initial drug susceptibility profile of M. tuberculosis among patients under TB programme in South India.
abstract: METHODS
  Pulmonary tuberculosis (PTB) patients enrolled for treatment at government health facilities in a sub-district of Thiruvallur district, Tamil Nadu, India.
  
  
  OBJECTIVE
  To determine the drug susceptibility profile among PTB patients admitted to treatment according to the Revised National Tuberculosis Control Programme (RNTCP).
  
  
  METHODS
  From May 1999 to December 2003, two additional sputum samples were collected from all patients at the start of anti-tuberculosis treatment under DOTS and were transported to a central laboratory for Mycobacterium tuberculosis culture and drug susceptibility testing (DST).
  
  
  RESULTS
  DST results were available for 1603 new sputum smear-positive patients; 85% of patients had organisms fully susceptible to streptomycin (S), isoniazid (H) and rifampicin (R), 10.4% any resistance to H and 1.7% to HR. Of 443 patients with history of previous anti-tuberculosis treatment, 59% had organisms susceptible to S, H and R, 37% had any resistance to H and 11.7% to HR.
  
  
  CONCLUSIONS
  The DST profile showed that the vast majority of patients have drug-susceptible organisms, and that currently recommended regimens under the RNTCP would be effective in the treatment of TB.
authors.affiliation: Tuberculosis Research Centre, Chennai, India.
authors.forename: T
authors.initials: T
authors.lastname: Santha
authors.forename: A
authors.initials: A
authors.lastname: Thomas
authors.forename: V
authors.initials: V
authors.lastname: Chandrasekaran
authors.forename: N
authors.initials: N
authors.lastname: Selvakumar
authors.forename: P G
authors.initials: PG
authors.lastname: Gopi
authors.forename: R
authors.initials: R
authors.lastname: Subramani
authors.forename: R
authors.initials: R
authors.lastname: Rajeswari
authors.forename: B
authors.initials: B
authors.lastname: Rani
authors.forename: C N
authors.initials: CN
authors.lastname: Paramasivan
authors.forename: M
authors.initials: M
authors.lastname: Perumal
authors.forename: F
authors.initials: F
authors.lastname: Wares
authors.forename: P R
authors.initials: PR
authors.lastname: Narayanan
mesh_terms: D000995:Antitubercular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification*; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use; D013307:Streptomycin / Q000494:pharmacology / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000382:microbiology*
chemical_list: D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin